Integrated Strategy Consulting and Investment Banking for Global Life Sciences

Data-Driven Strategy + Investment Banking

Back Bay is the only life sciences group that integrates seasoned strategic insight with investment banking capabilities to provide comprehensive guidance to global life sciences companies and their investors. Our team has the expertise to advise clients through complex business, scientific and financial challenges.

Boutique Feel + Global Reach

Global biotech. Pharmaceutical. Medical Device Companies. Investors. Academic centers of technology development. Government incubators. These are the organizations that rely on Back Bay for strategic guidance and responsive client service across their commercial, R&D, corporate business development and investment banking opportunities in the US and around the world.

DNB//Back Bay Partnership

A unique integrated strategy and corporate and investment banking solution for global and emerging life science and healthcare companies.

The DNB//Back Bay Healthcare Partnership provides essential strategic and financial support to healthcare companies.

Learn about the partnership

Featured

Apr 30, 2025

MARKET UPDATE

Market Update for Week of May 2, 2025

Apr 30, 2025

MARKET UPDATE

The Week at a Glance:

Market Rebound Continues: Although the Nasdaq and S&P 500 recouped all of its losses since “Liberation Day” on April 2nd, the effect of policy changes in DC ranging from tariffs to agency cuts will most likely result in continued market volatility

FDA Delays First PDUFA Date: Stealth BioTherapeutics reported that its rare disease drug was delayed last week, reinforcing concerns many in the industry had that the Trump administration’s agency cuts will impede drug approvals

M&A Finally Sees Some Action: Last week saw two notable M&A transactions – Merck KGaA’s acquisition of the oncology focused SpringWorks Therapeutics and Novartis’ acquisition of Regulus Therapeutics’ nephrology pipeline

These transactions mark the first meaningful deal announcements since early April

READ FULL UPDATE >

Apr 30, 2025

MARKET UPDATE

Featured

Obesity Drug Development: Still Room to Grow

Feb 17, 2025

Healthcare Analyst Report

Obesity Drug Development: Still Room to Grow

Feb 17, 2025

Healthcare Analyst Report

The second in our series of healthcare development reports focuses on the clinical and market needs within the GLP-1 space and how biopharma, investors and academia view the next obesity breakthrough.

Read More →

Feb 17, 2025

Healthcare Analyst Report

White Papers and Articles

Jan 20, 2025

BBLSA White Paper

Exploring the US-China Biotech Boom

Jan 20, 2025

BBLSA White Paper

As 2024 drew to a close, a surge of Chinese dealmaking led many industry watchers to wonder if a transformative shift in the biotech industry has begun—one that could profoundly impact the future of early-stage drug development.

Read More →

Jan 20, 2025

BBLSA White Paper

Featured

As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access

Feb 28, 2025

Article

As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access

Feb 28, 2025

Article

With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.

Read More →

Feb 28, 2025

Article

Featured

May 2, 2025

Events

BIO International

May 2, 2025

Events

DNB//Back Bay is pleased to sponsor the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

Read More →

May 2, 2025

Events

Life Sciences Development and Commercialization Financing

We guide biotech, pharmaceutical and medical technology companies and their investors on the development, commercialization, growth and maintenance of market share, by providing the insight needed to drive growth and create value. Together we can capitalize on opportunity, increase shareholder value and improve patient care.